A Research Guide for
Living with Sjögren’s Syndrome

PHASE 3 POSITIVE Ianalumab is a monoclonal antibody targeting the BAFF receptor on B cells. The Phase 3 NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials were the first randomized, placebo-controlled Phase 3 trials to meet their primary endpoint in primary Sjögren’s. They demonstrated statistically significant improvement in the ESSDAI (EULAR Sjögren’s Syndrome Disease Activity Index) compared to placebo. This is a watershed moment — no drug had ever achieved this in a Phase 3 Sjögren’s trial. Ianalumab is given as a subcutaneous injection monthly. Regulatory submission to the FDA is anticipated.

INVESTIGATIONAL Iscalimab blocks the CD40 pathway, which is critical for B-cell activation and the formation of germinal centers where autoantibodies are produced. The Phase 2b TWINSS trial showed improvements in disease activity and salivary gland function. This represents a novel mechanism that could complement or provide an alternative to B-cell depletion approaches.

INVESTIGATIONAL Remibrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling. BTK inhibitors have transformed treatment for B-cell lymphomas and are now being studied in autoimmune diseases. Early data in Sjögren’s show improvement in disease activity scores. As an oral drug, it would offer convenience over injectable therapies.

ESTABLISHED The 2016 ACR/EULAR Classification Criteria provided the first internationally validated, evidence-based criteria for Sjögren’s. They use a weighted scoring system where anti-SSA/Ro positivity and a positive salivary gland biopsy carry the highest weight. These criteria have improved diagnostic consistency across centers and are used as the standard entry criteria for clinical trials.

• Anti-SSA/Ro antibodies: The most important blood test for Sjögren’s. Positive in approximately 60–70% of primary Sjögren’s patients. A positive anti-SSA/Ro is worth 3 points in the ACR/EULAR criteria (out of 4 needed for classification). However, ~30% of patients are seronegative — a negative test does not rule out Sjögren’s.
• Anti-SSB/La antibodies: Positive in approximately 30–40% of patients, almost always in conjunction with anti-SSA/Ro. Less specific for Sjögren’s but supports the diagnosis when present.
• Rheumatoid factor (RF): Positive in approximately 50–60% of Sjögren’s patients. Not specific but contributes to the clinical picture.
• ANA (antinuclear antibody): Positive in approximately 80% of patients but not specific. Used as a screening test.
• Complement levels (C3, C4): Low complement, especially C4, may indicate more active systemic disease and is associated with higher lymphoma risk.
• Immunoglobulin levels: Hypergammaglobulinemia (elevated IgG) is common and reflects B-cell overactivity.
• ESR and CRP: May be elevated during active disease but are often normal in Sjögren’s.
• Complete blood count: May show cytopenias (low white blood cells, low platelets) in some patients.

• Schirmer’s test: A small strip of filter paper is placed under the lower eyelid for 5 minutes. Less than 5 mm of wetting is considered abnormal. Simple but somewhat imprecise — results vary with the environment and the patient’s state.
• Ocular staining score (OSS): The eye surface is stained with fluorescein and lissamine green dyes, and the cornea and conjunctiva are examined under a slit lamp for damage. A score of 5 or more (out of 12) is considered positive and is worth 1 point in the ACR/EULAR criteria.
• Tear break-up time (TBUT): Measures how quickly the tear film breaks apart after blinking. Less than 10 seconds is abnormal. Quick and noninvasive.

A minor salivary gland biopsy involves removing a small cluster of salivary glands from the inside of the lower lip under local anesthesia. This is the most specific test for Sjögren’s.

• What they look for: Focal lymphocytic sialadenitis with a focus score of 1 or more (one or more foci of 50+ lymphocytes per 4 mm² of glandular tissue). This is worth 3 points in the ACR/EULAR criteria.
• When it is needed: Particularly important for seronegative patients (negative anti-SSA/Ro) who still have strong clinical suspicion. If anti-SSA/Ro is positive, biopsy may not be necessary depending on the clinical picture.
• Risks: Generally well-tolerated. Minor lip numbness (~5–10% of cases, usually temporary) is the main risk.

• Unstimulated whole salivary flow rate: Saliva is collected over 15 minutes. A rate of 0.1 mL/min or less is considered abnormally low and is worth 1 point in the ACR/EULAR criteria.
• Salivary gland ultrasound: Increasingly used as a noninvasive alternative or complement to biopsy. Shows characteristic changes (inhomogeneity, hypoechoic areas) in affected glands. Not yet part of the formal classification criteria but widely used in Europe and increasingly in the US.
• Salivary scintigraphy: Nuclear medicine scan showing salivary gland function. Used less frequently than ultrasound in current practice.

• Have you tested for anti-SSA/Ro and anti-SSB/La antibodies?
• Should I have a salivary gland biopsy, or is my antibody result sufficient for diagnosis?
• Have you checked my complement levels (C3, C4) and immunoglobulin levels?
• Should I see an ophthalmologist for formal dry eye assessment?
• Could another condition be causing my symptoms (medications, other autoimmune diseases, hepatitis C)?
• Do I have primary or secondary Sjögren’s?
• What is my ESSDAI score, and how active is my disease systemically?
• Should salivary gland ultrasound be part of my evaluation?

Understanding why your doctors ordered specific tests — and what a positive or negative result means — helps you be a better-informed participant in your diagnosis.

• Labial salivary gland biopsy (3 points): A minor surgical procedure in which a small piece of tissue is removed from the inner lip. A pathologist looks for clusters of immune cells (called “foci”) attacking the gland tissue. A “focus score” of 1 or more means at least 50 immune cells per 4 square millimeters of tissue — clear evidence of autoimmune gland damage. The biopsy is the most definitive single test and is essential if blood tests are negative (seronegative Sjögren’s).
• Anti-SSA/Ro antibody (3 points): The blood test most associated with Sjögren’s. A simple blood draw. Positive in approximately 60–70% of primary Sjögren’s patients. Note: anti-SSA/Ro is NOT specific to Sjögren’s — it can also be positive in lupus. That’s why a positive result alone doesn’t diagnose Sjögren’s; it must be combined with symptoms and objective tests.
• Ocular staining score (1 point): An ophthalmologist applies a dye (lissamine green or rose bengal) to the eye and examines the cornea and conjunctiva for staining patterns. Staining reveals damaged or dying cells on the eye surface. A score of 5 or more indicates significant surface damage consistent with Sjögren’s.
• Schirmer’s test (1 point): A strip of filter paper is placed under the lower eyelid for 5 minutes. At the end, the length of the wet portion is measured. 5 mm or less indicates severely reduced tear production. This is one of the simplest, cheapest tests — but it can have false positives (including crying, reflex tearing from irritation) and false negatives (some patients have very low production but score just above 5 mm).
• Unstimulated salivary flow rate (1 point): You spit (or drool) into a tube for a set period without stimulating saliva (no chewing, no citrus). The volume collected is measured. 0.1 mL/min or less indicates very low salivary production. Simpler and faster than biopsy, but less specific.

Adding up to 4: Anti-SSA/Ro (3) + any one objective test (1) = 4 points = classifies as SS. Alternatively, biopsy (3) + any one objective test (1) = 4 points. Some patients reach 4 via three different 1-point objective tests plus serology at a lower level, but the most common paths are the two above.

Approximately 30% of people with primary Sjögren’s have negative anti-SSA/Ro blood tests. This is called “seronegative Sjögren’s.” It is one of the most frustrating aspects of getting diagnosed: you have all the symptoms, but the most widely ordered blood test comes back negative.

Why does this happen? Anti-SSA/Ro negativity in SS can reflect: different disease mechanisms (not all SS is driven by the same autoimmune pathways), early disease before antibodies have developed, or assay-related issues (different labs use different tests that can give discordant results).

What to do if you’re seronegative:

• Don’t give up on the diagnosis. Seronegative SS is a recognized entity. Your rheumatologist should know about it.
• Request a salivary gland biopsy. This is the key diagnostic test in seronegative patients. A positive biopsy (3 points) plus any one objective test (Schirmer’s, ocular staining, or salivary flow: 1 point each) reaches the threshold of 4 points needed for classification, even without anti-SSA/Ro.
• Complete objective tests. Ensure all three objective tests have been performed: Schirmer’s, ocular staining score, and unstimulated salivary flow. Collecting points from multiple tests can help reach the threshold.
• Ask about salivary gland ultrasound. This non-invasive imaging test can show structural damage to the salivary glands consistent with Sjögren’s. It is not yet part of the official scoring system but is increasingly used to guide decisions about biopsy.
• Consider a second opinion at a specialized center. Centers that see large numbers of Sjögren’s patients (Johns Hopkins, NIH/NIDCR, Penn SS Center) have extensive experience with seronegative presentations. A rheumatologist who sees SS only occasionally may be less familiar with the seronegative diagnostic pathway.
• Ask about re-testing. Anti-SSA/Ro levels can fluctuate, especially in early disease. In some cases, a repeat test months later turns positive as disease evolves.

• What is my ACR/EULAR classification score, and which specific tests contributed to it?
• If I scored below 4, is the diagnosis still possible based on my overall clinical picture?
• Should I have a labial salivary gland biopsy given my symptoms and test results?
• Am I anti-SSA/Ro positive? Is anti-Ro52 or anti-Ro60 separately reported on my test?
• Has my doctor looked at salivary gland ultrasound as an additional diagnostic tool?
• If this is secondary Sjögren’s (associated with another disease), how does that change my management?
• How confident are you in the Sjögren’s diagnosis given my specific results?
• Should I be referred to a Sjögren’s specialist for diagnostic confirmation?

• Preservative-free artificial tears are the first line. Use them frequently — every 1–2 hours during the day for severe dryness. Preserved drops can cause irritation with frequent use.
• Gel drops or ointments at night provide longer-lasting moisture during sleep when tears are not being produced.
• Lipid-containing tears may help if meibomian gland dysfunction (clogged oil glands in the eyelids) coexists.
• Avoid drops that claim to “get the red out” (vasoconstrictors) — these can worsen dryness.

• Cyclosporine ophthalmic (Restasis): FDA-APPROVED FOR DRY EYE Reduces inflammation on the eye surface and may help restore some tear production. Takes 3–6 months for full effect. Stinging on application is common but usually improves over time. Use twice daily.
• Lifitegrast (Xiidra): FDA-APPROVED FOR DRY EYE Blocks T-cell-mediated inflammation. May work faster than cyclosporine. Common side effect: dysgeusia (altered taste). Use twice daily.
• Perfluorohexyloctane (Miebo): FDA-APPROVED 2023 First eye drop specifically targeting tear evaporation rather than production. May be helpful when meibomian gland dysfunction contributes to dryness.
• Short-term topical corticosteroids: Used for acute flares of ocular surface inflammation. Not for long-term use due to risks (glaucoma, cataracts). Prescribed and monitored by an ophthalmologist.

• Punctal plugs: Tiny plugs inserted into the tear ducts to keep tears on the eye surface longer. Can be temporary (dissolving) or semi-permanent (silicone). Effective for many patients. Risk of epiphora (excess tearing) if residual tear production is higher than expected.
• Punctal cautery: Permanent closure of the tear ducts for patients who respond well to plugs.
• Scleral lenses: Large contact lenses that vault over the cornea, creating a fluid reservoir that continuously bathes the eye. Highly effective for severe dry eye that does not respond to drops. Requires fitting by a specialist.
• Autologous serum tears: Eye drops made from the patient’s own blood serum, containing growth factors that promote healing of damaged corneal tissue. Used for severe cases. Require a blood draw and compounding pharmacy.

• Should I be using preservative-free tears, and how often?
• Would a prescription anti-inflammatory drop (cyclosporine or lifitegrast) help me?
• Should I be evaluated for punctal plugs?
• Is my ocular surface damage getting worse, and how are we monitoring it?
• Should I see a corneal specialist or dry eye specialist?
• Are scleral lenses an option for my severity level?

Not all dry eye in Sjögren’s works the same way. There are two main types, and many people have both at once:

• Aqueous-deficient dry eye: The lacrimal (tear-producing) glands are damaged by the autoimmune attack, so they produce too few tears. This is the primary mechanism in Sjögren’s. Treatment focuses on replacing or conserving tears (drops, punctal plugs, secretagogues) and reducing inflammation on the eye surface (cyclosporine, lifitegrast).
• Evaporative dry eye (meibomian gland dysfunction / MGD): The meibomian glands, which produce the oily outer layer of the tear film that prevents evaporation, become blocked or dysfunctional. Tears evaporate too fast even when production is normal. This can coexist with Sjögren’s in 40–60% of patients. Treatment adds: warm compresses (10 minutes daily), lid massage, omega-3 supplementation, and possibly intense pulsed light (IPL) therapy performed by an ophthalmologist.

How to know which type you have: An ophthalmologist can assess your tear film lipid layer, check for meibomian gland plugging, and measure tear evaporation rate. Ask specifically about meibomian gland evaluation if you feel your drops aren’t working well enough — a lipid drop (like Systane Complete or Refresh Optive Mega-3) may work better than an aqueous-only drop if evaporative loss is a component.

Newer options for severe or treatment-resistant dry eye: Varenicline nasal spray (Tyrvaya) stimulates tear production through a completely different mechanism (nasal reflex arc stimulation). Cenegermin (Oxervate) is a nerve growth factor drop specifically for neurotrophic keratopathy — a complication where corneal sensation is lost, preventing healing. Ask your ophthalmologist if either might apply to your case.

For patients with moderate-to-severe aqueous-deficient dry eye that does not respond adequately to drops, plugs, and anti-inflammatory medications, there are more advanced options that can dramatically improve quality of life. These require specialized fitting at a cornea or dry eye center.

Scleral contact lenses. Standard contact lenses rest on the cornea and can worsen dry eye. Scleral lenses are large-diameter lenses (15–24 mm) that vault entirely over the cornea, resting on the white of the eye (sclera). The space between the lens and the cornea is filled with saline solution, creating a permanent fluid reservoir that continuously bathes the damaged corneal surface. This can convert severe, painful dry eye into a manageable condition. Advantages: wear throughout the day; compatible with glasses; can correct vision; the saline reservoir provides a much more stable surface than any drop. Disadvantages: requires fitting by a specialist, trial-and-error to find the right lens design, some learning curve to insert and remove. Insurance coverage varies; often covered for keratoconjunctivitis sicca with documented corneal damage.

PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem). PROSE is a type of custom-fitted scleral lens developed at Boston Foundation for Sight. It is specifically designed for severe ocular surface disease including Sjögren’s-related KCS. Each device is individually manufactured to the shape of the patient’s eye. Studies show that patients with Sjögren’s KCS experience significant improvements in visual acuity, pain, and functional vision. PROSE fitting is available at selected US centers (Boston Foundation for Sight, VA centers nationwide, some academic ophthalmology programs). Ask your rheumatologist for a referral if standard treatment is inadequate.

Autologous serum eye drops. Made from the patient’s own blood serum (drawn by a lab, processed to remove red cells, then diluted with saline and dispensed as eye drops). Serum contains growth factors (EGF, TGF-β), fibronectin, and vitamins that normal tears contain but artificial tears do not. Proven to improve corneal staining, symptoms, and healing of persistent epithelial defects in Sjögren’s KCS. A rheumatology center prescription, lab draw, and compounding pharmacy are all required; the drops must be refrigerated. Cost can be a barrier; check if your insurance covers compounded autologous serum under your medication benefit.

• Pilocarpine (Salagen): FDA-APPROVED A cholinergic agonist that stimulates residual salivary gland function. Typical dose is 5 mg three times daily. Takes 6–12 weeks for full effect. Side effects include sweating (~40%), increased urination, and flushing. Contraindicated in uncontrolled asthma and narrow-angle glaucoma.
• Cevimeline (Evoxac): FDA-APPROVED Another cholinergic agonist with more selective muscarinic M3 receptor activity. Typical dose is 30 mg three times daily. May have fewer side effects than pilocarpine for some patients. Also stimulates tear production.
• Sugar-free gum and lozenges: Xylitol-containing products are preferred because xylitol inhibits cavity-causing bacteria.
• Saliva substitutes: Over-the-counter sprays and rinses that provide temporary moisture. Many patients find them less effective than natural saliva stimulation but useful at night.
• Hydration: Frequent sips of water throughout the day. Humidifiers at night.

• Prescription fluoride: High-concentration fluoride toothpaste (1.1% sodium fluoride or stannous fluoride) and custom fluoride trays used daily. This is not optional — it is essential.
• Dental visits every 3–4 months (not the standard 6 months) for cleaning and monitoring.
• Avoid sugary foods and acidic drinks. Without saliva to buffer acid and wash away sugar, these cause rapid enamel destruction.
• Chlorhexidine rinses: May be recommended by your dentist to control bacterial load.
• Find a dentist who understands Sjögren’s. Most dentists are not trained in managing autoimmune-related oral dryness. An oral medicine specialist or a dentist affiliated with a Sjögren’s center is ideal.

• Oral candidiasis (thrush): Very common in Sjögren’s because saliva has antifungal properties. May present as white patches, redness, angular cheilitis (cracking at the corners of the mouth), or a burning sensation. Treated with antifungal lozenges, rinses, or occasionally oral fluconazole.
• Bacterial sialadenitis: Infection of the salivary glands, presenting as painful swelling (usually of the parotid gland). Treated with antibiotics, massage, warm compresses, and sialogogues (saliva-stimulating agents).

• Should I try pilocarpine or cevimeline to stimulate saliva production?
• Can you prescribe high-concentration fluoride toothpaste and custom trays?
• How often should I see a dentist with my level of dryness?
• Should I see an oral medicine specialist?
• Am I at risk for oral candidiasis, and should I be on preventive treatment?
• What saliva substitutes do you recommend for nighttime?

Saliva does far more than keep the mouth moist. It lubricates food for chewing and swallowing, contains enzymes that begin digestion, and provides much of the sensory experience of taste. When saliva is severely reduced, eating can become painful, laborious, and anxiety-provoking.

Swallowing difficulties (dysphagia): Without adequate saliva, dry food does not form a proper bolus (food ball) and can be difficult or even dangerous to swallow. Practical adaptations include:

• Always sip water with every bite of food. Keep a water glass on the table at all times.
• Choose soft, moist, or sauced foods (gravies, soups, smoothies, yogurt, eggs). Avoid dry crackers, bread without spread, raw hard vegetables.
• Cut food into small pieces. Take small bites and chew thoroughly.
• Avoid eating while lying down or immediately before bed.
• Ask your doctor about a swallowing evaluation (speech-language pathology) if dysphagia is causing choking, painful swallowing, or significant weight loss.

Taste disturbance: Saliva is required for taste molecules to reach taste receptor cells. Severe dry mouth can cause food to taste bland, metallic, or even unpleasant. Hydration (frequent sips) and pilocarpine/cevimeline may partially restore taste. Some patients find that adding sauces, spices (non-acidic), and strong flavors compensates for reduced taste sensitivity. Avoid extremely acidic foods (citrus, vinegar) as these can cause additional damage to dry oral tissues.

Nighttime management: Dry mouth is typically worst at night when salivary flow naturally decreases during sleep. Strategies: bedroom humidifier (40–60% humidity); glass of water on nightstand; OraCoat XyliMelts applied to the inside of the cheek at bedtime (these adhere slowly throughout the night); biotene oral rinse before sleep; avoiding alcohol-containing mouthwash (highly drying). Mouth breathing from nasal congestion dramatically worsens nighttime xerostomia — address any nasal obstruction (allergies, septal deviation) that forces mouth breathing during sleep.

Tooth loss is a real outcome for many Sjögren’s patients. Despite aggressive prevention, some patients lose multiple teeth due to root caries, severe enamel erosion, or late-diagnosed disease. Understanding the options for tooth replacement in the context of dry mouth is important.

Dental implants and dry mouth. Dental implants (titanium posts that integrate into the jawbone and support a crown) can be successful in Sjögren’s patients, but require careful planning. Dry mouth does not directly prevent osseointegration (the process of the implant bonding to bone). However: (1) Candida colonization and bacterial overgrowth around implants are higher in dry mouth; vigilant oral hygiene around implants is essential; (2) Salivary secretory IgA, which normally protects the peri-implant tissue, is reduced in SS; (3) Some immunosuppressants used for systemic SS (corticosteroids, methotrexate) may impair bone healing. Work with an oral medicine specialist who understands SS before undergoing implants.

Dentures and dry mouth. Conventional dentures require adequate saliva to provide suction and a comfortable fit. In severe xerostomia, dentures are poorly retained, cause mucosal irritation, and increase the risk of oral candidiasis under the denture base. Options: denture adhesives to improve retention; well-fitted implant-supported dentures (which do not rely on suction); more frequent denture cleanings with antifungal soaks (nystatin suspension or miconazole gel). Never sleep in dentures — this dramatically increases candida risk.

Accessing dental care for Sjögren’s. Many dentists do not have specific training in managing autoimmune-related xerostomia. Options for better dental care: university dental schools with oral medicine departments; the Sjögren’s Foundation maintains a provider directory of SS-knowledgeable dental providers (sjogrens.org); academic medical center dentistry departments affiliated with rheumatology clinics. When you find an appropriate dentist, share your complete medication list (including hydroxychloroquine, immunosuppressants, and any drugs with anticholinergic effects) and your most recent ESSDAI score as context for the severity of your systemic disease.

• Reported by approximately 70–80% of Sjögren’s patients
• Rated as the most disabling symptom by many patients, worse than dryness
• Poorly correlated with disease activity markers — blood tests may look “fine” while fatigue is severe
• May be worsened by coexisting conditions: sleep disruption from dryness, depression, hypothyroidism, anemia, fibromyalgia
• No specific treatment has been proven effective in randomized trials

• Evaluate for treatable contributing factors: Thyroid function (hypothyroidism is common in autoimmune patients), hemoglobin (anemia), vitamin D levels, sleep quality, depression screening.
• Activity pacing: Plan activities with rest periods. Accept that you may need to do less than before the diagnosis.
• Exercise: Regular low-to-moderate exercise (walking, swimming, yoga) has the strongest evidence for improving autoimmune-related fatigue. Start slowly and gradually increase.
• Hydroxychloroquine: Some patients report improved fatigue on hydroxychloroquine, though randomized trial evidence (JOQUER) did not confirm this. May be worth trying given its overall safety profile.
• Cognitive behavioral therapy (CBT): Can help develop coping strategies for chronic fatigue.
• Sleep hygiene: Address nocturnal dryness (humidifier, eye ointment, sips of water at bedside) to improve sleep quality.

• Arthralgia (joint pain): Common in Sjögren’s, typically non-erosive (does not destroy joints like rheumatoid arthritis). Usually involves small joints of the hands, wrists, and knees.
• Treatment: NSAIDs (ibuprofen, naproxen) for mild-moderate pain. Hydroxychloroquine is commonly used. Short courses of low-dose corticosteroids for flares. Methotrexate may be considered for persistent inflammatory arthritis.
• Fibromyalgia overlap: Approximately 20–30% of Sjögren’s patients also have fibromyalgia. The widespread pain and fatigue can be difficult to distinguish from Sjögren’s-related symptoms. Fibromyalgia-specific treatments (duloxetine, pregabalin, exercise) may be helpful in addition to Sjögren’s management.

• Have you checked my thyroid function, vitamin D, and hemoglobin recently?
• Could my fatigue be related to a medication side effect?
• Should I be screened for fibromyalgia or depression?
• Is hydroxychloroquine appropriate for my joint pain and fatigue?
• Can you refer me to a physical therapist or exercise program?
• Are there any clinical trials targeting fatigue in Sjögren’s?

• Airway dryness, chronic cough, and recurrent bronchitis are common
• Interstitial lung disease (ILD) affects approximately 10–20% of patients and can range from mild to progressive
• Lymphocytic interstitial pneumonia (LIP) is the most characteristic pattern
• Monitoring: pulmonary function tests (PFTs) and high-resolution CT if symptomatic
• Treatment may include corticosteroids, mycophenolate, or rituximab depending on severity

• Tubulointerstitial nephritis is the most common renal manifestation, causing renal tubular acidosis (RTA)
• Presents with low potassium, metabolic acidosis, kidney stones, and sometimes muscle weakness
• Glomerulonephritis is less common but more serious, often associated with cryoglobulinemia
• Monitoring: regular kidney function tests, urinalysis, electrolytes

• Peripheral neuropathy: Affects approximately 10–20% of patients. Can cause numbness, tingling, burning pain, especially in the feet and hands. Small fiber neuropathy is the most common form and may not show up on standard nerve conduction studies — skin biopsy for nerve fiber density may be needed for diagnosis.
• Central nervous system involvement: Less common but can include cognitive difficulties (“brain fog”), CNS vasculitis, optic neuritis, or myelitis.
• Neurological involvement can precede sicca symptoms and may be the presenting feature of Sjögren’s.

• Cutaneous vasculitis (small-vessel inflammation) manifests as purpura (small red or purple spots on the skin, usually on the legs)
• Associated with cryoglobulinemia, low complement, and higher disease activity
• Vasculitis is a marker for more aggressive systemic disease and higher lymphoma risk
• Treatment depends on severity: mild cases may respond to hydroxychloroquine; moderate-severe cases may require corticosteroids, azathioprine, or rituximab

• What is my ESSDAI score, and what organ systems are involved?
• Should I have pulmonary function tests or a chest CT?
• Could my neuropathy symptoms be related to Sjögren’s?
• Are my complement levels and cryoglobulins being monitored?
• Is my disease activity high enough to warrant systemic therapy?
• Should I be on lymphoma surveillance given my risk factors?

Brain fog — difficulty concentrating, memory lapses, word-finding problems, mental fatigue — affects approximately 30–50% of Sjögren’s patients and is one of the most underrecognized and underreported symptoms. Patients often feel embarrassed about these symptoms and don’t mention them to their doctors. They should.

Causes of cognitive symptoms in Sjögren’s:

• Autoimmune mechanism: Anti-neuronal antibodies (anti-Ro antibodies can affect the nervous system), microvasculitis, and inflammatory mediators crossing into the brain can directly impair cognition. This is a real inflammatory/autoimmune cause, not psychological.
• Sleep deprivation: Nocturnal dryness (dry mouth, dry eyes, interrupted sleep for sips of water) severely disrupts sleep quality, which worsens cognitive function independently of disease activity.
• Fibromyalgia overlap: Fibrofog (cognitive dysfunction from fibromyalgia) is very similar to SS brain fog. If fibromyalgia is a coexisting condition, addressing it with appropriate treatment can improve cognition.
• Hypothyroidism: Always check thyroid function. Hypothyroidism causes cognitive slowing that mimics SS brain fog exactly. Treatment with levothyroxine can produce dramatic improvement.
• Depression: Cognitive symptoms are a core feature of depression, which is more common in Sjögren’s. This is a treatable condition — asking for depression screening is appropriate.
• Medication side effects: Anticholinergic drugs (including some antihistamines, bladder medications, and antidepressants) cause cognitive clouding. Review your medication list with your doctor for anticholinergic burden.

What helps: Sleep optimization (humidifier, nighttime drops, treating insomnia); thyroid optimization; fibromyalgia treatment; medication review; cognitive rehabilitation strategies (written lists, structured routines, calendar use). Neuropsychological testing can document and track cognitive changes. Some patients show improvement with immunosuppression when cognitive symptoms are directly related to active systemic SS; others require symptom management focused on the sleep/fibromyalgia/depression contributors.

Cardiac involvement in Sjögren’s is less common than in lupus or scleroderma but does occur and can be serious. The most important manifestations to know about:

• Pericarditis: Inflammation of the sac around the heart, causing sharp chest pain that worsens lying down and improves leaning forward. Usually responds to NSAIDs or colchicine. Report any unexplained chest pain to your doctor immediately.
• Congenital heart block (in neonates of anti-SSA/Ro+ mothers): This is a serious fetal complication, not an adult cardiac issue. See the pregnancy section of this guide for details.
• Autonomic neuropathy affecting the heart: The automatic nervous system can be affected, causing heart rate irregularities, orthostatic hypotension (dizziness when standing), and exercise intolerance. These are neurological manifestations that happen to affect cardiovascular function.
• Accelerated cardiovascular disease: Chronic systemic inflammation increases cardiovascular risk, similar to lupus and rheumatoid arthritis. Good control of blood pressure, cholesterol, and blood sugar; exercise; and not smoking are especially important for Sjögren’s patients. Discuss cardiovascular risk reduction specifically with your rheumatologist and primary care doctor.
• Raynaud’s phenomenon: Color changes of the fingers and toes (white → blue → red) triggered by cold or stress are common in Sjögren’s. Mild Raynaud’s is managed with warm clothing and hand warmers. More severe cases may need medication (calcium channel blockers, sildenafil).

When to call immediately: Any chest pain, shortness of breath, palpitations, or sudden dizziness in a patient with Sjögren’s warrants urgent medical evaluation — do not attribute these symptoms to Sjögren’s without ruling out cardiac causes.

Renal tubular acidosis (RTA) is the most common kidney problem in Sjögren’s and is often missed because it does not cause protein or blood in the urine — the hallmarks most people (and many doctors) associate with kidney problems. Instead, the kidney’s acid-handling tubules are attacked by the immune system, causing the blood to become too acidic (metabolic acidosis) and the body to waste potassium in the urine.

How RTA presents. Symptoms include: unexplained muscle weakness or cramps (from low potassium); fatigue disproportionate to other SS activity; kidney stones (acid urine promotes stone formation, especially calcium phosphate stones); bone pain (acid leaches calcium from bones over time). Blood tests show: low potassium (hypokalemia); low bicarbonate (metabolic acidosis); high urine pH (>5.5 despite acidosis, because the kidney cannot acidify the urine properly). RTA can exist for years undetected if potassium and bicarbonate are not measured regularly.

Treatment and monitoring. Mild RTA: potassium citrate or sodium bicarbonate supplementation to correct the acid-base imbalance. Potassium replacement for symptomatic hypokalemia. Severe RTA: may warrant systemic immunosuppression (hydroxychloroquine, low-dose prednisone) to address the underlying autoimmune tubular injury. Once identified, RTA should be monitored with regular electrolytes and kidney function tests. For patients with recurrent kidney stones: a 24-hour urine collection to assess stone risk and guide prevention (increased fluid, citrate supplementation). Ask your rheumatologist: “Have my electrolytes been checked specifically for potassium and bicarbonate levels?”

OFF-LABEL — COMMONLY USED The most frequently prescribed systemic drug for Sjögren’s. Used for joint pain, fatigue, and as a general immune modulator.

• Evidence: The JOQUER trial (a randomized, placebo-controlled trial) did not show significant benefit on its primary endpoint (composite of dryness, pain, and fatigue). However, hydroxychloroquine remains widely used based on clinical experience and subgroup analyses suggesting benefit for articular and constitutional symptoms.
• Dose: Typically 200–400 mg daily (not exceeding 5 mg/kg/day to minimize retinal toxicity risk).
• Monitoring: Annual ophthalmologic exam (including OCT) after 5 years of use (or earlier if additional risk factors) to screen for retinal toxicity.
• Advantages: Well-tolerated, low cost, minimal immunosuppression, may reduce flares.

OFF-LABEL — USED FOR SYSTEMIC DISEASE A B-cell depleting antibody used for moderate-to-severe systemic manifestations (vasculitis, cytopenias, severe parotid swelling, neuropathy, ILD).

• Evidence: The TRACTISS trial (randomized, placebo-controlled in primary Sjögren’s) did not meet its primary endpoints (oral dryness VAS and fatigue VAS at 48 weeks). However, rituximab showed improvements in unstimulated salivary flow and ESSDAI in post-hoc analyses. It is widely used for severe systemic manifestations despite the negative trial.
• Dose: Typically 1000 mg IV on days 1 and 15, repeated every 6 months based on clinical response.
• Monitoring: Immunoglobulin levels (IgG) before each cycle — hypogammaglobulinemia is a risk with repeated courses. Hepatitis B screening before first dose.
• Risks: Infusion reactions, infections, progressive multifocal leukoencephalopathy (PML, extremely rare). May worsen hypogammaglobulinemia already present in some Sjögren’s patients.

OFF-LABEL Used for interstitial lung disease, glomerulonephritis, and other organ-threatening manifestations.

• Evidence: Small case series and retrospective studies only. No randomized controlled trial in Sjögren’s.
• Dose: Typically 1–3 g daily in divided doses.
• Monitoring: CBC every 4–8 weeks (cytopenias), liver function.
• Risks: GI side effects (nausea, diarrhea), infection risk, teratogenicity (must not be used during pregnancy).

• Methotrexate: Occasionally used for inflammatory arthritis in Sjögren’s, similar to its use in rheumatoid arthritis. Limited evidence specific to Sjögren’s.
• Azathioprine (Imuran): Used as a steroid-sparing agent for systemic manifestations. Limited evidence.
• Corticosteroids: Used for acute flares of systemic disease (vasculitis, severe parotid swelling, cytopenias, ILD flares). Should be used at the lowest effective dose for the shortest possible time due to long-term side effects. NOT recommended for routine management of dryness or fatigue.

PHASE 3 POSITIVE Ianalumab depletes B cells through the BAFF receptor pathway. The NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials met their primary endpoint, demonstrating significant improvement in ESSDAI compared to placebo. Administered as a monthly subcutaneous injection. This represents the first positive Phase 3 result in Sjögren’s history and could lead to the first FDA-approved systemic therapy for the disease.

INVESTIGATIONAL Iscalimab blocks the CD40 pathway, a co-stimulatory signal required for B-cell activation and germinal center formation. Unlike B-cell depletion, this approach modulates B-cell function rather than eliminating B cells entirely. Phase 2b data showed improvements in ESSDAI and salivary gland function. Phase 3 trials are planned or underway (see NCT04541589, NCT03905525 — completed Phase 2 studies).

INVESTIGATIONAL A selective, covalent BTK inhibitor that blocks B-cell receptor signaling. Oral dosing. Phase 2 data showed improvement in disease activity. BTK inhibitors are already approved for B-cell lymphomas (ibrutinib, acalabrutinib, zanubrutinib) and are being explored across autoimmune diseases (verify current trials on ClinicalTrials.gov).

• Nipocalimab (anti-FcRn): Reduces IgG antibody levels by blocking their recycling. Studied in the Phase 2 DAHLIAS trial (NCT04968912) in Sjögren’s and across multiple autoimmune diseases. A novel approach that could reduce pathogenic autoantibodies in Sjögren’s.
• Telitacicept (dual BAFF/APRIL inhibitor): Targets both BAFF and APRIL, which may provide more comprehensive B-cell suppression than BAFF alone. Phase 2/3 studies ongoing (search ClinicalTrials.gov by "telitacicept Sjogren" for current enrollment).
• Deucravacitinib (TYK2 inhibitor): JAK pathway inhibitor being studied in autoimmune conditions. Oral dosing.
• CAR-T cell therapy for autoimmune disease: Anti-CD19 CAR-T has shown dramatic responses in individual cases of refractory autoimmune disease. Still very early for Sjögren’s, but actively investigated at several academic centers.

NEPTUNUS-1 and NEPTUNUS-2 achieving their primary endpoint is genuinely historic. But what does “Phase 3 positive” mean in practice, and what should patients realistically expect?

What it proved: Ianalumab reduced disease activity in the ESSDAI (a clinical score measuring systemic inflammation across 12 organ domains) compared to placebo, in patients with moderate-to-severe active disease. This is the first time any drug has proven this in a properly designed Phase 3 trial for Sjögren’s.

What it did NOT prove: Ianalumab is unlikely to significantly improve dryness in patients who already have severe glandular damage from years of disease — the glands cannot regenerate. It reduces ongoing systemic inflammation, not already-established architectural damage. Expect better results in patients with active systemic manifestations (joints, lungs, nervous system involvement) than in those whose main issue is pure dryness from long-standing gland destruction.

When might it be available? FDA regulatory review typically takes 6–12 months after a complete application. If filing occurs in 2025–2026, approval could come in 2026–2027. Verify with your rheumatologist or at Novartis’s pipeline website. If ianalumab receives FDA approval, insurance coverage will likely require prior authorization; your rheumatologist will need to document your ESSDAI score and prior treatment history.

What this change means longer term: The success of the NEPTUNUS design (ESSDAI endpoint + active disease enrichment) establishes a blueprint for future SS trials. Other drugs now in Phase 2/3 (iscalimab, remibrutinib) are using similar designs. The SS treatment landscape 5 years from now may include multiple approved options for different patient profiles. This is a genuine paradigm shift after 25+ years of failed trials.

• Persistent parotid gland swelling: Especially if hard, fixed, or progressively enlarging over weeks to months
• Declining C4 complement levels
• Cryoglobulinemia (abnormal proteins in the blood that precipitate in the cold)
• Monoclonal gammopathy (a single abnormal immunoglobulin band on serum protein electrophoresis)
• Lymphadenopathy (enlarged lymph nodes)
• Purpura (small red/purple spots on the skin)
• High ESSDAI score at diagnosis

What to do: Report any persistent parotid swelling or new lumps to your rheumatologist promptly. Regular monitoring of complement levels, serum protein electrophoresis, and immunoglobulin levels is recommended for patients with risk factors. A biopsy of any suspicious mass is essential.

A 5–10% lifetime risk sounds alarming in isolation. Let’s put it in context so you can think about it clearly rather than anxiously.

The general population baseline: The lifetime risk of non-Hodgkin lymphoma in the general US population is approximately 2%. The Sjögren’s risk (~7% lifetime) is about 3–5x higher. That sounds large, but it still means 90–95% of SS patients will never develop lymphoma.

The type of lymphoma matters: The most common SS-associated lymphoma is MALT (mucosa-associated lymphoid tissue) lymphoma, which typically arises in the parotid gland. MALT lymphoma is generally slow-growing (indolent), has excellent prognosis with appropriate treatment (local radiation or rituximab), and is often detected at an early stage. It is a very different disease than the aggressive lymphomas people commonly fear.

Your personal risk depends on specific factors: The LYMFOS risk model gives you a structured way to think about your personal risk. Five factors each add 1 point: (1) persistent parotid gland swelling; (2) lymphadenopathy (enlarged lymph nodes); (3) low C4 complement; (4) cryoglobulinemia; (5) monoclonal gammopathy. Zero risk factors: ~2% lifetime (close to general population). 1 risk factor: ~5%. 2+ risk factors: ~25%. Ask your rheumatologist where you stand on these factors. If you have none, the elevated worry may not be warranted. If you have 2+, your rheumatologist should be monitoring you more intensively.

How monitoring reduces harm: The whole point of surveillance (parotid exam, SPEP, complement levels, LDH) is to catch lymphoma early when it is most treatable. Early-stage parotid MALT lymphoma treated with local radiation has a 5-year progression-free survival of approximately 75%. Advanced lymphoma caught later is harder to treat. Consistent follow-up appointments — even when you feel well — are how early detection happens.

Most SS patients will never see these symptoms. But if you do, prompt action matters:

• New or enlarging lump in the parotid gland (in front of/below the ear, or inside the cheek near the back teeth): Do not watch and wait for more than 2–4 weeks. Report this to your rheumatologist immediately for ultrasound evaluation. A hard, fixed, progressively growing parotid mass is especially urgent. A soft, fluctuant parotid swelling that comes and goes (especially with eating) is more likely benign sialadenitis, but still needs evaluation.
• Enlarged lymph nodes that persist for more than 4 weeks: Especially in the neck, armpit, or groin. Brief lymph node swelling from infections is normal; persistent enlargement is not.
• B-symptoms — the lymphoma red-flag triad: Unexplained fever (>38.5°C / 101.3°F for more than 2 weeks without infection), unexplained night sweats severe enough to soak through clothes, and unexplained weight loss (>10% of body weight in 6 months). Any one of these warrants urgent medical evaluation. All three together is a medical urgency.
• Worsening purpura (skin spots) combined with any of the above: Cryoglobulinemic vasculitis evolving toward lymphoma can present this way.
• Rapidly declining IgG or rapidly rising paraprotein (monoclonal band on SPEP): Your rheumatologist will track these; if you notice your blood tests showing these trends, ask what they mean for your lymphoma risk.

The most important single action: Maintain your regular rheumatology appointments even when you feel well. Physical examination of the parotid glands, ordering SPEP and complement levels, and examining you for lymphadenopathy are things your doctor can only do if you come in.

Because no systemic therapies are FDA-approved specifically for Sjögren’s, insurance coverage can be unpredictable and difficult. Here is a practical guide to navigating access:

Hydroxychloroquine: Generally covered by insurance for Sjögren’s on an off-label basis, as it is cheap and low-risk. If denied, appeal with documentation of diagnosis and physician letter of medical necessity.

Rituximab: More expensive, more likely to require prior authorization. Insurance typically requires documentation of: confirmed SS diagnosis (classification criteria met), specific systemic indication (vasculitis, cytopenias, ILD, or severe parotid disease), and prior failure of HCQ or equivalent. EULAR 2020 recommendations can be cited in appeal letters as international guideline support. If denied after initial appeal, request a peer-to-peer review (your rheumatologist speaks directly to the insurance medical director).

If ianalumab is approved: Expect prior authorization requirements to include ESSDAI ≥5, anti-SSA/Ro positivity, and documentation of prior treatment. Start gathering this documentation now: ESSDAI scores at each visit, anti-SSA/Ro titer, prior therapy history. Your rheumatologist’s office will navigate the authorization process, but being proactive helps.

Clinical trial enrollment as access: Patients with ESSDAI ≥5 who cannot access rituximab may be eligible for trials providing the investigational drug at no cost. Major active trial sites: Johns Hopkins (Maryland), NIH/NIDCR (Maryland), University of Pennsylvania (Philadelphia), Mayo Clinic (Rochester, MN), University of Utah (Salt Lake City). Search ClinicalTrials.gov with your zip code to find the nearest open trial.

Sjögren’s Foundation advocacy program: The Foundation engages with insurance companies and policymakers on access issues. Contact 1-800-475-6473 for patient navigation assistance.

Sjögren’s doesn’t take a vacation. Here is how to plan for travel without compromising your care:

Medication considerations when traveling abroad:

• Hydroxychloroquine: Available in most countries, but under different brand names. Carry a sufficient supply plus a 2-week buffer. Bring your prescription documentation and a letter from your rheumatologist stating the diagnosis and medical necessity.
• Pilocarpine / cevimeline: Pilocarpine is available internationally. Cevimeline (Evoxac) is US-only — if you rely on cevimeline, bring your full supply. Do not assume it will be available at your destination.
• Rituximab: If you are on a rituximab dosing schedule, coordinate your infusion timing to occur before or after a trip, not during. IV infusions abroad are complicated by different products, different protocols, and cost uncertainty.
• Artificial tears: Many preservative-free drops are available internationally but brands and formulations differ. Carry at least a 2-week supply of your preferred brand, especially for remote destinations.

Environmental considerations:

• Air travel: Airplane cabin air is extremely dry (10–20% humidity). Use preservative-free drops every 1–2 hours during flights. Drink water continuously. Avoid alcohol and caffeine (both dehydrate). Use ointment-based eye drops before sleep during long-haul flights.
• Dry climates: Deserts and high altitudes worsen sicca. Bring extra drops and a travel-size humidifier if staying more than a few days. Portable ultrasonic humidifiers are small enough for carry-on luggage.
• Cold climates: Cold air, forced heating (also very dry), and cold-triggered Raynaud’s. Layer up; use room humidifiers; pack hand warmers and warm gloves.

Emergency care abroad: Carry an emergency medical card that lists your Sjögren’s syndrome diagnosis, current medications, your rheumatologist’s contact information, and any allergies. In a medical emergency abroad: English-speaking rheumatology is available at academic medical centers in most major European, Asian, and Canadian cities. The US Embassy can provide a list of recommended English-speaking physicians in most countries.

PRIMARY ENDPOINT NOT MET The TRACTISS trial was a randomized, placebo-controlled trial of rituximab in primary Sjögren’s. It did not meet its co-primary endpoints (oral dryness VAS and fatigue VAS at 48 weeks). Despite this, rituximab remains in off-label use for severe systemic disease based on improvements in secondary endpoints and clinical experience. This highlights the difficulty of conducting trials in Sjögren’s and choosing the right endpoints.

PRIMARY ENDPOINT NOT MET The JOQUER trial, a randomized placebo-controlled trial of hydroxychloroquine in primary Sjögren’s, did not show significant benefit on its composite primary endpoint (proportion of patients with improvement in at least 3 of 5 symptoms: dryness, pain, fatigue, tender point count, global assessment). Despite this, hydroxychloroquine continues to be widely prescribed for Sjögren’s-related arthralgia and is considered safe for long-term use with appropriate monitoring.

FAILED IN SJÖGREN’S Belimumab (Benlysta) targets soluble BAFF (BLyS), the same pathway targeted by ianalumab but through a different mechanism. While approved for systemic lupus, the BELISS study in Sjögren’s showed limited efficacy. The difference may be because ianalumab targets the BAFF receptor directly and depletes B cells, while belimumab only neutralizes soluble BAFF. This distinction illustrates why specific drug-target selection matters.

MIXED RESULTS Abatacept (Orencia) blocks T-cell co-stimulation. Phase 2 studies showed some improvements in disease activity but results were inconsistent across trials, and Phase 3 development for Sjögren’s has not been pursued. It is approved for rheumatoid arthritis.

• Humidifiers: Use in the bedroom and workspace. Aim for 40–50% humidity. This helps eyes, nose, mouth, and skin.
• Water bottles everywhere: Carry water at all times. Keep water at the bedside, desk, car, and bag.
• Eye protection: Wraparound glasses or moisture chamber glasses reduce tear evaporation, especially outdoors, in wind, or in air-conditioned environments.
• Avoid drying medications when possible: Antihistamines (cetirizine, diphenhydramine), decongestants, certain antidepressants (tricyclics), and anticholinergics all worsen dryness. Discuss alternatives with your doctor.
• Diet modifications: Soft, moist foods are easier to eat with dry mouth. Avoid hard, dry, spicy, or acidic foods that irritate dry oral tissues. Take sips of water with meals.

• Validate the fatigue. Chronic fatigue in Sjögren’s is real, immune-mediated, and not a character failing. Saying “you don’t look sick” is unhelpful.
• Sjögren’s Foundation (sjogrens.org): National organization with patient education, support groups, clinical trial information, and advocacy. Call: 1-800-475-6473.
• Online communities: The Sjögren’s Foundation forums and social media groups connect patients with shared experiences.
• Mental health: Depression and anxiety are more common in Sjögren’s patients. This is partly biological (immune-mediated) and partly a response to living with chronic disease. Seeking mental health support is a sign of strength, not weakness.

• Anti-SSA/Ro and pregnancy: Anti-SSA/Ro antibodies can cross the placenta and, in approximately 1–2% of pregnancies, cause neonatal lupus including congenital heart block. Women with anti-SSA/Ro antibodies who are pregnant or planning pregnancy should have specialized monitoring with fetal echocardiography starting at 16–18 weeks.
• Medication safety: Hydroxychloroquine is considered safe and often recommended to continue during pregnancy. Methotrexate and mycophenolate are absolutely contraindicated in pregnancy. Discuss all medications with your rheumatologist before conceiving.
• Coordinate care with a maternal-fetal medicine specialist experienced with autoimmune pregnancies.

Sjögren’s is an invisible illness. You may look healthy while experiencing profound fatigue, cognitive dysfunction, and pain that make sustained work extremely difficult. Knowing your rights and options is important.

Workplace accommodations (ADA, in the US): The Americans with Disabilities Act (ADA) requires employers with 15+ employees to provide “reasonable accommodations” for documented disabilities. Sjögren’s qualifies. Reasonable accommodations might include: flexible hours or remote work (for fatigue and medical appointments); rest breaks; ergonomic equipment; access to a humidifier or water at the workstation; reduced lighting for photosensitive eyes; noise-reduction for brain-fog-related concentration issues. To request accommodations: speak with your HR department, complete the employer’s accommodation request process, and ask your rheumatologist for documentation (a letter describing your diagnosis, limitations, and recommended accommodations).

Short-term disability (STD): If a flare prevents you from working for weeks to months, short-term disability insurance (provided by your employer or purchased individually) can replace a portion of your income. Document your symptoms and limitations carefully with your medical team during flares for disability insurance purposes.

Long-term disability (LTD) and SSDI: For patients unable to maintain employment due to severe Sjögren’s (rare but real), long-term disability insurance or Social Security Disability Insurance (SSDI) may be applicable. SSDI applications for Sjögren’s are often initially denied; working with a disability attorney who specializes in chronic illness improves approval rates. The Sjögren’s Foundation can provide guidance on navigating this process.

Having an honest conversation with your employer: Disclosing a chronic illness is a personal decision. You are not legally required to disclose a specific diagnosis. However, providing enough information to justify accommodations (rather than just seeming unreliable) often protects your employment. Frame it in terms of what you need, not what’s wrong with you: “I have a chronic health condition that sometimes affects my energy levels. I’d like to discuss flexible scheduling to ensure I can consistently meet my responsibilities.”

Sjögren’s patients typically see 4–6 different specialists: rheumatologist, ophthalmologist, dentist (ideally oral medicine), primary care physician, and potentially a pulmonologist, neurologist, or nephrologist if systemic complications develop. Coordinating this team is real work that the patient is often left to do themselves.

Practical strategies for multi-specialist coordination:

• Keep a master medication list: A single document with every medication, dose, prescribing physician, indication, and start date. Update it at every visit and carry it to all appointments. Share it proactively — don’t assume providers communicate with each other.
• Designate a “captain” of your team: Your rheumatologist should be the primary coordinator of your SS management, but this only works if you actively communicate what other specialists are doing. Send your rheumatologist visit summaries from ophthalmology and dentistry. Send your ophthalmologist updates on any changes to your SS medication that might affect ocular management (e.g., hydroxychloroquine retinal monitoring).
• Use patient portals: Most health systems now offer patient portals where you can review your labs, send messages to providers, and access visit summaries. Use them to track trends in key labs (IgG, C4, complement, SPEP) over time.
• Bring a support person to complex appointments: Rheumatology appointments covering ESSDAI scores, systemic involvement, and medication decisions involve a lot of information. A trusted person who knows your medical history can help you remember what was discussed and ask follow-up questions you might miss when you’re focused on answering the doctor’s questions.
• Prepare a one-page summary for new providers: Date of SS diagnosis, antibody status, current ESSDAI, organ involvement, current medications, recent key lab values, and known medication allergies. New emergency room doctors, urgent care providers, or specialist consultants need this information and may not have time to navigate your full chart.
• Track symptoms between appointments: A brief daily log (energy level 1–10, dryness 1–10, any new symptoms) makes for much more useful appointments than trying to recall how you’ve been over the past 3 months from memory. Apps like Bearable or a simple notes document work well.

Sjögren’s care is expensive. Biologics (rituximab, ianalumab when approved) run $15,000–$50,000+ per year; prescription eye drops (cyclosporine, lifitegrast) can cost $400–$600/month; dental care is an ongoing major expense. There are real programs that help.

Pharmaceutical manufacturer assistance. Most manufacturers of high-cost drugs have patient assistance programs (PAPs) for patients who cannot afford their medications: Genentech (rituximab/Rituxan): ACCESS Solutions program — free drug for eligible uninsured/underinsured patients. Abbvie (adalimumab), Janssen (infliximab), and other biologics have similar programs. For prescription eye drops: Allergan (Restasis), Novartis (Xiidra) both have copay assistance cards for commercially insured patients that can reduce out-of-pocket to $0 for eligible patients. Search [drug name] + “patient assistance program” or check NeedyMeds.org for a comprehensive database.

Non-profit and disease-specific assistance. HealthWell Foundation: provides copay assistance for biologic medications for autoimmune conditions — contact 800-675-8416 or healthwellfoundation.org. Patient Advocate Foundation: helps navigate insurance denials, appeals, and access issues — patientadvocate.org. Sjögren’s Foundation: limited financial assistance programs and patient navigation — sjogrens.org, 800-475-6473. Patient Access Network (PAN) Foundation: copay and cost assistance for biologics — panfoundation.org. RxAssist.org: database of patient assistance programs for specific drugs.

Dental care financial assistance. Dental school clinics provide full dental services at reduced cost with supervision from experienced faculty — excellent for complex SS dental care at a fraction of private practice cost. State dental association programs: many states have programs connecting low-income patients with volunteer dental providers. CareCredit and Compassionate Finance: healthcare-specific financing for large dental bills. Some states have Medicaid dental benefits for adults — check your state’s Medicaid dental coverage, which has expanded significantly in recent years. The Sjögren’s Foundation can help connect patients with resources in their area.